Evidence map›Paper›PMID 42458173›Full record

ReviewDrug safety2026

Augmenting Medical Judgment in Signal Confirmation: Design Considerations for an AI-Enabled Causality Assessment Framework.

Tarek A Hammad, Justine Rochon, Salman Afsar, Sue H Lee, Dona M Ely, Neda Hassanpour, Andrew Bate

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tarek A HammadPatient Safety and Pharmacovigilance (PSPV), Takeda Development Center Americas, Inc., Cambridge, USA. Tarek.hammad@takeda.com.ORCID http://orcid.org/0000-0001-8229-4716
Justine RochonR&D Data and Quantitative Sciences, Takeda Development Center Americas, Inc., Cambridge, MA, USA.ORCID http://orcid.org/0009-0000-2868-1870
Salman AfsarWorldwide Patient Safety, Bristol Myers Squibb, Princeton, USA.
Sue H LeePatient Safety and Pharmacovigilance (PSPV), Takeda Development Center Americas, Inc., Cambridge, USA.
Dona M ElyPatient Safety and Pharmacovigilance (PSPV), Takeda Development Center Americas, Inc., Cambridge, USA.
Neda HassanpourR&D Technology Services, Takeda Development Center Americas, Inc., Cambridge, USA.
Andrew BateSafety Innovation and Analytics, GSK, Philadelphia, USA.ORCID http://orcid.org/0000-0003-3151-3653

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The safety signal assessment process evaluates the potential causal association between a medicinal product and a specific adverse event by integrating multiple streams of evidence. Existing causality assessment methods remain challenged by the considerable manual effort involved and by decision variability, even when drawing on the same underlying domains of evidence. This work addresses the need in contemporary pharmacovigilance for a more efficient and harmonized approach to signal confirmation that preserves scientific rigor while mitigating the limitations of the current assessment processes. To address this need, the article describes design considerations for an artificial intelligence (AI)-enabled, integrated approach for safety signal causality assessment, referred to as Signal Confirmation through Omnichannel Pharmacovigilance Evidence (PV-SCOPE). As a conceptual proof-of-principle, the proposed approach describes how the Hammad-Afsar holistic causality assessment framework could be operationalized through multimodal evidence integration and structured approach, while preserving the central role of clinical and scientific reasoning in causality assessment. Because the AI workflow is presented as a design-oriented framework rather than a completed or validated model, the article focuses on architectural logic, governance, and validation and regulatory requirements rather than reporting performance results.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.